EXL launches EXLerate.AI platform to drive accelerated AI business benefits at scale for enterprises
EXLerate.AI orchestrates data, digital, and domain-specialized AI solutions to transform mission-critical operations
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a leading data and AI company, announced EXLerate.AI, its agentic AI platform designed to help enterprises reimagine workflows with the ability to seamlessly integrate EXL and third-party AI agents into their business operations. The new platform accelerates progress on the path to greater efficiency, enhanced customer experience, improved accuracy and increased scalability across business operations, resulting in a better return on investment from AI.
EXLerate.AI is an open, cloud-agnostic, and modular orchestration platform, allowing for fast implementation in all client environments. It includes more than 10 industry-specific EXL-built AI agents already in use across insurance, healthcare, retail, utilities and financial services. Clients benefit from EXL's deep data and domain knowledge, data models and knowledge graphs and retain the flexibility to incorporate third party or internal AI agents, as well as current digital systems. Out-of-the-box capabilities improve the effectiveness of processes such as claims adjudication, commercial underwriting, payment servicing, customer service, internal audit, energy billing, accounts payable and legacy code migration.
The biggest challenge enterprises are facing when it comes to implementing AI is integrating it across workflows seamlessly. By providing an orchestration solution with embedded high value AI agents, clients can now scale AI across their businesses in a hybrid environment.
'Our teams have spent more than two years working with partners and clients to enhance our AI solutions platform to include our proprietary LLMs, AI agents, knowledge graphs and data models to help businesses harness AI and redesign workflows without getting bogged down by technical complexities,' said Anand 'Andy' Logani, EXL's chief digital and AI officer. 'We invested in EXLerate.AI with three core principles in mind: a strong data and domain foundation, flexibility for rapid innovation and the ability to integrate AI seamlessly into enterprise operations.'
Unlike most AI solutions, which perform a single task, EXLerate.AI orchestrates multiple AI models, alongside human expertise and other AI-powered analytics. EXL will continue to innovate at a rapid pace and invest in the development of new AI solutions across key functions in insurance, healthcare, banking and capital markets, and other industries.
Key capabilities of EXLerate.AI include:
AI Agents and Accelerators: The platform supports more than 100 accelerators designed to enhance automation and efficiency at speed and scale. EXLerate.AI also incorporates a growing library of domain-specific AI agents that can dynamically interact with enterprise systems, streamlining processes, enhancing decision making and improving customer experiences.
Domain Specific Large Language Models (LLMs): EXLerate.AI includes two newly developed, proprietary LLMs for health and finance. These specialized AI models are trained on domain-specific data, building on the EXL Insurance LLM that was introduced in 2024 to support critical claims and underwriting tasks. With 25 years of domain expertise and proprietary, industry-specific labeled data, EXL's LLMs deliver unmatched accuracy, efficiency, and compliance, outperforming generic models.
Open Architecture Platform: Building on EXL's deep data management and domain-specific knowledge, EXLerate.AI offers an open architecture platform, ensuring clients have flexibility and are not locked into a single platform. The platform is fully compatible with existing enterprise IT systems and is pre-integrated with technology from industry leaders that are important to our clients, including, NVIDIA, AWS, Google, Microsoft, ServiceNow and Salesforce.
Learn more about EXLerate.AI at EXL's AI in Action event on March 5, 2025 at https://www.exlservice.com/ai-in-action-driving-the-shift-to-scalable-AI.
About EXL
EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 57,000 employees spanning six continents. For more information, visit www.exlservice.com.
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL's control. Forward-looking statements include information concerning EXL's possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as 'may,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate' or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation, recessionary economic trends, and ability to successfully integrate strategic acquisitions, are discussed in more detail in EXL's filings with the Securities and Exchange Commission, including EXL's Annual Report on Form 10- K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by applicable law.
ContactsMedia Keith Little+1 703-598-0980 media.relations@exlservice.com
Investor RelationsJohn Kristoff+1 212 209 4613IR@exlservice.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region
KFSHRC accounts for 52.4% of all active clinical trials in Saudi Arabia. RIYADH, Saudi Arabia, June 04, 2025 (GLOBE NEWSWIRE) -- As part of Saudi Arabia's broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom's leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of KFSHRC's Clinical Trials Transformation Initiative, launched in 2021 to build an integrated, patient-centered research ecosystem. By the end of 2024, the hospital had recorded 701 active research proposals, representing an 8% increase over the previous year. In Riyadh alone, research approvals rose by 20%, demonstrating growing alignment between scientific discovery and clinical care delivery. KFSHRC's research growth was matched by key innovation milestones. In 2024, it became the first in Saudi Arabia to locally produce CAR-T cells — a major step toward national self-sufficiency in advanced therapies. It also delivered a breakthrough in hemophilia care, using one-time gene therapy to restore clotting function in eight patients, eliminating preventive treatment and significantly improving quality of life. These advancements align closely with Saudi Arabia's Vision 2030 and National Biotechnology Strategy, which designate biotechnology as a national priority sector — aiming to localize therapeutic development, accelerate innovation, and establish global leadership by 2040. Complementing its scientific leadership, KFSHRC has also invested in public engagement, launching awareness campaigns in high-traffic public venues to promote Clinical Trials literacy and reduce misconceptions around participation. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally among the world's top 250 Academic Medical Centres for the third consecutive year, and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at mediacoverage@ A photo accompanying this announcement is available at
Yahoo
an hour ago
- Yahoo
As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options
Spherix Global Insights' new patient audit on transfusion-dependent thalassemia reveals strong physician interest in emerging treatments like mitapivat and etavopivat, and provides insight into ideal candidates for curative gene therapies. EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent thalassemia patients remain tethered to long-term transfusion support. Transfusions, while providing symptom relief, in turn create logistical barriers and their own clinical challenges. New data from Spherix Global Insights' independent chart audit, Patient Chart Dynamix™: Transfusion Dependent Thalassemia 2025 (US), is based on insight from 81 real-world patient charts submitted by 49 US-based hematologists. These data paint a complex picture of therapeutic inertia, growing anticipation for emerging treatments, and deep-seated frustration with limitations of current treatment options. Most transfusion-dependent beta thalassemia patients follow some regular transfusion schedule. That said, many receive them at relatively extended intervals: often once a month or even less frequently, though a small subset still require more frequent transfusions. This variation in treatment patterns, along with persistent symptoms and unmet needs highlighted in the chart audit, points to a strong opportunity for new therapies to improve care for a broad range of patients. Among surveyed hematologists, mitapivat (Agios) currently holds a slight edge in name recognition over etavopivat (Novo Nordisk). Interestingly, despite this difference in familiarity, physicians identified slightly more patients as potential candidates for etavopivat, hinting at a broader perceived clinical fit once awareness and understanding of the agent catch up. Chart audit data allows users to probe further into specific patient types which physicians perceive as better fits for either agent, as well as those who they do not perceive as candidates. This growing interest in emerging oral therapies reflects a broader desire among hematologists for more accessible, lower-burden treatment options. While most patients are theoretically eligible for curative approaches like gene therapy, the market still favors lower-barrier alternatives. These alternatives include oral therapies that do not require referral to specialized centers or extensive pre-conditioning, and brands with which they are more familiar given other indications such as Reblozyl (Bristol Myers Squibb). Disease-modifying therapies that are easier to prescribe and integrate into routine practice have the promise to significantly improve the lives of patients who would not qualify or want gene therapy. Access barriers compound the issue, with over half of physicians voicing frustration over payer restrictions that make it difficult to initiate optimal care. These challenges highlight a critical need – not just for clinical innovation, but also for strong manufacturer support in navigating reimbursement and expanding access. As the beta thalassemia landscape continues to evolve, hematologists are increasingly looking toward emerging therapies that are easier to prescribe, carry fewer logistical burdens than gene therapy, and offer clear reductions in transfusion dependency. Products like mitapivat and etavopivat are well-positioned to address this gap, assuming familiarity, confidence, and access grow in tandem – but the goal to cure patients of hemoglobinopathies still carries heavy weight, with desire to treat with gene therapy consistently growing. Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the 'why' behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284 in to access your portfolio
Yahoo
an hour ago
- Yahoo
Fermilab: Muon g-2 announces most precise measurement of the magnetic anomaly of the muon
The third and final result, based on the last three years of data, is in perfect agreement with the experiment's previous results, further solidifying the experimental world average. This long-awaited value will be the world's most precise measurement of the muon magnetic anomaly for many years to come. Muon g-2 ring Results plot graph Batavia, Ill., June 04, 2025 (GLOBE NEWSWIRE) -- Scientists working on the Muon g-2 experiment, hosted by the U.S. Department of Energy's Fermi National Accelerator Laboratory, have released their third and final measurement of the muon magnetic anomaly. This value is related to g-2, the experiment's namesake measurement. The final result agrees with their published results from 2021 and 2023 but with a much better precision of 127 parts-per-billion, surpassing the original experimental design goal of 140 parts-per-billion. 'The anomalous magnetic moment, or g–2, of the muon is important because it provides a sensitive test of the Standard Model of particle physics. This is an exciting result and it is great to see an experiment come to a definitive end with a precision measurement,' said Regina Rameika, the U.S. Department of Energy's Associate Director for the Office of High Energy Physics. This long-awaited result is a tremendous achievement of precision and will remain the world's most precise measurement of the muon magnetic anomaly for many years to come. Despite recent challenges with the theoretical predictions that reduce evidence of new physics from muon g-2, this result provides a stringent benchmark for proposed extensions of the Standard Model of particle physics. 'This is a very exciting moment because we not only achieved our goals but exceeded them, which is not very easy for these precision measurements,' said Peter Winter, a physicist at Argonne National Laboratory and co-spokesperson for the Muon g-2 collaboration. 'With the support of the funding agencies and the host lab, Fermilab, it has been very successful overall, as we reached or surpassed pretty much all the items that we were aiming for.' 'For over a century, g-2 has been teaching us a lot about the nature of nature,' said Lawrence Gibbons, professor at Cornell University and analysis co-coordinator for this result. 'It's exciting to add a precise measurement that I think will stand for a long time.' The Muon g-2 (pronounced 'gee minus two') experiment looks at the wobble of a fundamental particle called the muon. Muons are similar to electrons but about 200 times more massive; like electrons, muons have a quantum mechanical property called spin that can be interpreted as a tiny internal magnet. In the presence of an external magnetic field, the internal magnet will wobble — or precess — like the axis of a spinning top. The precession speed in a magnetic field depends on properties of the muon described by a number called the g-factor. Theoretical physicists calculate the g-factor based on the current knowledge of how the universe works at a fundamental level, which is contained in the Standard Model of particle physics. Nearly 100 years ago, the value of g was predicted to be 2. But experimental measurements soon showed g to be slightly different from 2 by a quantity known as the magnetic anomaly of the muon, aμ, calculated with (g-2)/2. The Muon g-2 experiment gets its name from this relation. The muon magnetic anomaly encodes the effects of all Standard Model particles, and theoretical physicists can calculate these contributions to an incredible precision. But previous measurements taken at Brookhaven National Laboratory in the late 1990s and early 2000s showed a possible discrepancy with the theoretical calculation at that time. When experiment doesn't align with theory, it could indicate new physics. Specifically, physicists wondered if this discrepancy could be caused by as-yet undiscovered particles pulling at the muon's precession. So physicists decided to upgrade the Muon g-2 experiment to make a more precise measurement. In 2013, Brookhaven's magnetic storage ring was transported from Long Island, New York, to Fermilab in Batavia, Illinois. After years of significant upgrades and improvements, the Fermilab Muon g-2 experiment started up on May 31, 2017. In parallel, an international collaboration of theorists formed the Muon g-2 Theory Initiative to improve the theoretical calculation. In 2020, the Theory Initiative published an updated, more precise Standard Model value based on a technique that uses input data from other experiments. The discrepancy with the result from that technique continued to grow in 2021 when Fermilab announced its first experimental result, confirming the Brookhaven result with a slightly improved precision. At the same time, a new theoretical prediction came out based on a second technique that heavily relies on computational power. This new number was closer to the experimental measurement, narrowing the discrepancy. Recently, the Theory Initiative published a new prediction combining the results of several groups that used the new computational technique. This result remains closer to the experimental measurement, dampening the possibility of new physics. However, the theoretical effort will continue to work to understand the discrepancy between the data-driven and computational approaches. The latest experimental value of the magnetic moment of the muon from the Fermilab experiment is: aμ = (g-2)/2 (muon, experiment) = 0.001 165 920 705 +- 0.000 000 000 114(stat.) +- 0.000 000 000 091(syst.) This final measurement is based on the analysis of the last three years of data, taken between 2021 and 2023, combined with the previously published datasets. This more than tripled the size of the dataset used for their second result in 2023, and it enabled the collaboration to finally achieve their precision goal proposed in 2012. It also represents an analysis of the experiment's best-quality data. Toward the end of their second data-taking run, the Muon g-2 collaboration finished tweaks and enhancements to the experiment that improved the quality of the muon beam and reduced uncertainties. The Muon g-2 collaboration describes the result in a paper that they submitted today to Physical Review Letters. 'As it has been for decades, the magnetic moment of the muon continues to be a stringent benchmark of the Standard Model,' said Simon Corrodi, assistant physicist at Argonne National Laboratory and analysis co-coordinator. 'The new experimental result sheds new light on this fundamental theory and will set the benchmark for any new theoretical calculation to come.' A future experiment at the Japan Proton Accelerator Research Complex will likely make another measurement of the muon magnetic anomaly in the early 2030s, but, initially, they won't achieve the same precision as Fermilab. Meanwhile, the Theory Initiative will continue working to resolve the inconsistency between their two theoretical predictions. The Muon g-2 collaboration is made up of nearly 176 scientists from 34 institutions in seven countries. Marco Incagli, a physicist with the Italian National Institute for Nuclear Physics at Pisa and co-spokesperson for Muon g-2, emphasized that the internationality of the collaboration was key to the success of the experiment. Unusually, the scientists also represent a variety of physics areas. 'This experiment is quite peculiar because it has very different ingredients in it,' said Incagli. 'It is really done by a collaboration among communities that normally work on different experiments.' Unlike other high-energy physics experiments, Muon g-2 needed more than just high-energy physicists; the collaboration is also composed of accelerator physicists, atomic physicists and nuclear physicists. 'It was very valuable to see that, when we had all these different experts come together, we could solve items that probably one group could not have done alone,' said Incagli. While the experiment's main analysis has come to an end, there is more to be mined from the six years of Muon g-2 data. In the future, the collaboration will produce measurements of a property of the muon called the electric dipole moment as well as tests of a fundamental property of physical laws known as charge, parity, and time-reversal symmetry. 'It's a really beautiful experiment,' said Gibbons. 'The data that comes out is really exquisite. It's been a privilege to have access to this data and analyze it.' 'Of course, it's sad to end such an endeavor because it's been a large part of many of our collaborators' lives,' said Winter, who has been part of the collaboration since 2011. 'But we also want to move to the next physics that's out there, to do our best to advance the field in other areas. 'I think it will be a textbook experiment that will be a long-lasting reference for many future decades to come,' Winter added. Fermi National Accelerator Laboratory is America's premier national laboratory for particle physics and accelerator research. Fermi Forward Discovery Group manages Fermilab for the U.S. Department of Energy Office of Science. Visit Fermilab's website at and follow us on social media. Attachments Muon g-2 ring Results plot graph CONTACT: Tracy Marc Fermilab 2242907803 TRACYM@ in to access your portfolio
